High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia
- Collection:
- Health Policy and Services Research
- Series Title(s):
- Research brief (Leonard Davis Institute of Health Economics)
- Author(s):
- Doshi, Jalpa A., author Li, Pengxiang, author Huo, Hairong, author Pettit, Amy R., author Kumar, Rishab, author Weiss, Brendan M., author Huntington, Scott F., author
- Contributor(s):
- Leonard Davis Institute of Health Economics, issuing body.
- Publication:
- Philadelphia, PA : Leonard Davis Institute of Health Economics, 2016
- Language(s):
- English
- Format:
- Text
- Subject(s):
- Cost Sharing Drug Costs Medicare Part D -- economics Financing, Personal Health Services Accessibility Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy Protein Kinase Inhibitors -- economics Protein Kinase Inhibitors -- therapeutic use Protein-Tyrosine Kinases -- antagonists & inhibitors Humans United States
- Genre(s):
- Technical Report
- Abstract:
- KEY FINDINGS: Medicare Part D beneficiaries with higher out-of-pocket costs are more likely to delay starting or not start a recommended specialty drug when newly diagnosed with leukemia. Policy changes are needed to ensure optimal access to specialty medications under Medicare Part D.
- Copyright:
- Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
- Extent:
- 1 online resource (1 PDF file (2 pages))
- Illustrations:
- Illustrations
- NLM Unique ID:
- 101680603 (See catalog record)
- Permanent Link:
- http://resource.nlm.nih.gov/101680603